|
||||||
 |
||||||
|
|
|
 |
|
          May 13, 2013
May 8, 2013
|
|
All prices delayed at least 15 minutes.
All prices delayed at least 20 minutes. |
|
Animal Health News ReleaseNew Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs
03/06/05 BELLEVILLE ON, June 3, 2005 – Bioniche Life Sciences Inc. (TSC: BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data from a study demonstrating the immunomodulatory activity of its Mycobacterial Cell Wall-DNA Complex (MCC) in dogs. The presentation, “Immunomodulatory Activity of Mycobacterial Cell Wall-DNA Complex (MCC) In Vitro and Following Intravenous Administration to Dogs”, took place at the 2005 Forum of the American College of Veterinary Internal Medicine in Baltimore, Maryland earlier this week: This presentation by Nathalie Saha of Bioniche Therapeutics evaluated the capacity of MCC to induce the synthesis of cytokines and chemokines from mononuclear cells in vitro and following its administration to dogs. “Our results show that MCC is an effective inducer of cytokines and chemokine synthesis by canine effector cells in a concentration-dependent manner in vitro,” noted Dr. Mario C. Filion, Head of Biomedical Research at Bioniche Therapeutics (the human health division of Bioniche Life Sciences Inc.). “Intravenous and intravesical administration of MCC also results in the induction of cytokine and chemokine synthesis, with a peak 3 to 6 hours following administration.” Dr. Nigel C. Phillips, Senior Vice-President of Scientific Affairs and Chief Scientific Officer of Bioniche Life Sciences Inc. added “These data support the concept of MCC as a bifunctional agent with immune stimulant and chemotherapeutic activities that has the ability to function as an anticancer agent in several species including man and dogs.” Added Graeme McRae, President & CEO of Bioniche Life Sciences Inc., “MCC should prove to be as effective in treating canine cancers as it is in treating human cancers. We have completed clinical studies in humans with bladder and prostate cancers, and have conducted pre-clinical studies in several other cancers with promising results.” About MCCMycobacterial Cell Wall-DNA Complex (MCC) is a non-viable cell wall composition prepared from the saprophytic microorganism Mycobacterium phlei. MCC acts as an immune stimulant and as a cell cycle arresting/proliferation-inhibiting and apoptosis (programmed cell death)-inducing agent for cancer cells. MCC contains mycobacterial DNA, which appears to be responsible for both of these activities. Bioniche has completed Phase II studies using MCC for the treatment of bladder cancer, and is currently planning a multi-centre Phase III clinical trial in North America and Europe.
About Canine CancerAmericans own approximately 73 million dogs . Almost two-thirds of American households include at least one dog, with approximately four dogs in every thousand diagnosed with cancer each year.2 1. 2005-2006 National Pet Owners Survey, American Pet Products Manufacturing Association, www.appma.org ###
|
|
Categories:
|
Copyright 2004, Bioniche Life Sciences Inc. All rights reserved | Legal Disclaimer | Privacy Policy